| Project/Area Number |
15H04598
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Veterinary medical science
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
MIZUNO TAKUYA 山口大学, 共同獣医学部, 教授 (90398826)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
富張 瑞樹 帯広畜産大学, 畜産学部, 准教授 (00552754)
中川 貴之 東京大学, 大学院農学生命科学研究科(農学部), 准教授 (40447363)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2017: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2016: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2015: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
|---|
| Keywords | dog / cancer / immune checkpoint / oncolytic virotherapy / DNA vaccine / 犬 / 腫瘍 / 免疫 / ガン / 治療 / レオウイルス |
|---|
| Outline of Final Research Achievements |
In this study, several clinical trials, such as oncolytic virotherapy using reovirus, DNA vaccine therapy, and PD-1 chimeric antibody therapy for canine cancer had been accomplished. Nineteen dogs with various tumors were enrolled for oncolytic virotherapy, which were evaluated. Several dogs showed clinical improvement. As as DNA vaccination therapy, novel adjuvant therapy had not established using mice model, but clinical trials had been done, and showed two dogs with malignant melanoma survived for more than 2 years. Regarding immunecheckpoint antibody therapy, PD-1 chimeric antibody therapy had been established based on monoclonal antibody against canine PD-1, which was developed in our laboratory and now has been evaluated for cancer-bearing dogs.
|
